Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + etoposide + cisplatin
- Development stage
- Phase 2
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
serplulimab + etoposide + cisplatin is a combination chemo-immunotherapy regimen being evaluated as a neoadjuvant treatment for limited-stage small cell carcinoma of the esophagus (SCCE). The regimen includes serplulimab (HLX10), a fully humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, which acts as an immune checkpoint inhibitor to enhance T-cell anti-tumor activity. This is combined with the cytotoxic agents etoposide, a topoisomerase II inhibitor, and cisplatin (or carboplatin), a platinum-based DNA alkylating agent. The combination is currently under investigation in a Phase II trial led by Fujian Cancer Hospital to assess its efficacy, specifically the pathological complete response (pCR) rate, and safety in patients with this rare esophageal malignancy.
- Brand names
- HANS狀
- Other names
- serplulimab + etoposide + platinum-based chemotherapyserplulimab + etoposide + carboplatin
02
Targets
DNATOP2A (DNA topoisomerase II)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on serplulimab + etoposide + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + etoposide + cisplatin.